Motexafin gadolinium: A novel redox active drug for cancer therapy
- 31 December 2006
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 16 (6), 466-476
- https://doi.org/10.1016/j.semcancer.2006.09.002
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Motexafin gadolinium induces mitochondriallymediated caspase-dependent apoptosisApoptosis, 2005
- Mechanistic Studies of Motexafin Gadolinium (Xcytrin®): A Redox Active Agent That Reacts with Electron-Rich Biological SubstratesPublished by American Chemical Society (ACS) ,2005
- Reductase‐mediated metabolism of motexafin gadolinium (Xcytrin®) in rat and human liver subcellular fractions and purified enzyme preparationsJournal of Pharmaceutical Sciences, 2005
- Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cellsBlood, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Pulse Radiolytic Studies of Metallotexaphyrins in the Presence of Oxygen: Relevance of the Equilibrium with Superoxide Anion to the Mechanism of Action of the Radiation Sensitizer Motexafin Gadolinium (Gd−Tex2+, Xcytrin)The Journal of Physical Chemistry B, 2001
- G6PD Deficient Cells and the Bioreduction of Disulfides: Effects of DHEA, GSH Depletion and Phenylarsine OxideBiochemical and Biophysical Research Communications, 2000
- Localization and Efficacy Analysis of the Phototherapeutic Lutetium Texaphyrin (PCI-0123) in the Murine EMT6 Sarcoma ModelPhotochemistry and Photobiology, 1997
- Enzymatic reduction of 5,5′-dithiobis-(2-nitrobenzoic acid) by lysate of rat liver mitochondriaThe International Journal of Biochemistry & Cell Biology, 1995
- The Pecking Order of Free Radicals and Antioxidants: Lipid Peroxidation, α-Tocopherol, and AscorbateArchives of Biochemistry and Biophysics, 1993